1-10 of 10
Duncan Walker, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations

Jennifer Kimberly Lue, MD, John S Manavalan, MD, Christine Klaus, BS, Rahul Kanik, PhD, Andre M. Grilo, PhD, Alice McDonald, PhD, Jared Gollob, PhD MD, Duncan Walker, PhD, Owen A. O'Connor, MD PhD, Nello Mainolfi, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12.
https://doi.org/10.1182/blood-2020-135898
Published: 2020
Journal Articles

Ktx-120, a Novel Irakimid Degrader of IRAK4 and IMiD Substrates Shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL CDX and PDX Models

Duncan Walker, PhD, Michele Mayo, Christine Klaus, BS, Dapeng Chen, PhD, Samyabrata Bhaduri, PhD, Kirti Sharma, Scott Rusin, Alice McDonald, PhD, Jared Gollob, PhD MD, Nello Mainolfi, PhD, Matt Weiss, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41.
https://doi.org/10.1182/blood-2020-137750
Published: 2020
Journal Articles

Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma

Haojing Rong, PhD, Kirti Sharma, Fred Csibi, Bin Yang, Scott Rusin, Yatao Shi, PhD, Joyoti Dey, PhD, Rahul Karnik, Michele Mayo, Karen Yuan, Yogesh Chutake, Alice McDonald, PhD, Sean Zhu, PhD, Nan Ji, PhD, Phillip Liu, PhD, Henry Li, PhD, Duncan Walker, PhD, Jared Gollob, PhD MD, Nello Mainolfi, PhD, Chris Desavi
Journal: Blood
Blood (2020) 136 (Supplement 1): 42.
https://doi.org/10.1182/blood-2020-137778
Published: 2020
Journal Articles

Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies

Fred Csibi, Nan Ji, PhD, Bin Yang, Karen Yuan, Michele Mayo, Haojing Rong, PhD, Scott Rusin, Kirti Sharma, Christine Loh, PhD, Henry Li, PhD, Sharon Townson, Jesse Chen, PhD, Hari Kamadurai, PhD, Duncan Walker, PhD, Jared Gollob, PhD MD, Nello Mainolfi, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3803.
https://doi.org/10.1182/blood-2019-128981
Published: 2019
Journal Articles

FT-1101: A Structurally Distinct Pan-BET Bromodomain Inhibitor with Activity in Preclinical Models of Hematologic Malignancies

David S Millan, PhD, Monica A Alvarez Morales, MS, Kenneth J Barr, PhD, Daniel Cardillo, MS, Alan Collis, PhD, Christopher J Dinsmore, PhD, Jaime A Escobedo, PhD, Kevin P Foley, PhD, Torsten Herbertz, PhD, Stephen Hubbs, BS, Goss S Kauffman, BS, Katherine J Kayser-Bricker, PhD, Mark T Kershaw, MSc, George P Luke, PhD, Matthew W Martin, PhD, Crystal McKinnon, BS, Rachel L Mendes, MS, Kristina R Muskiewicz, MA, Shawn ER Schiller, MS, Patricia Soulard, MS, Adam C Talbot, PhD, Duncan Walker, PhD, Lili Yao, MS, Grace L Williams, PhD
Journal: Blood
Blood (2015) 126 (23): 1367.
https://doi.org/10.1182/blood.V126.23.1367.1367
Published: 2015
Journal Articles

ARRY-520 Combined With Pomalidomide Displays Enhanced Anti-Tumor Activity In Preclinical Models Of Multiple Myeloma

Michael J Humphries, PhD, Deborah Anderson, Lance Williams, Rob Rieger, Brian Tunquist, PhD, Duncan Walker, PhD
Journal: Blood
Blood (2013) 122 (21): 3167.
https://doi.org/10.1182/blood.V122.21.3167.3167
Published: 2013
Journal Articles

Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low α-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study

Sagar Lonial, M.D., Jatin J. Shah, M.D., Jeffrey Zonder, M.D., William I. Bensinger, MD, Adam D. Cohen, MD, Jonathan L. Kaufman, MD, Ajay K. Nooka, MD, MPH, Donna M. Weber, M.D., Brandi Hilder, Selena A Rush, BS, Ann Ptaszynski, Duncan Walker, PhD, Robert Z. Orlowski, M.D., Ph.D.
Journal: Blood
Blood (2013) 122 (21): 285.
https://doi.org/10.1182/blood.V122.21.285.285
Published: 2013
Journal Articles

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

Jatin J. Shah, M.D., Jeffrey A. Zonder, MD, Adam Cohen, MD, William Bensinger, MD, Jonathan L. Kaufman, MD, Robert Z. Orlowski, M.D., Ph.D., R. Donald Harvey, PharmD, Muneer H. Abidi, MD, Sheeba K. Thomas, MD, Duncan Walker, PhD, Brandi Hilder, Ann Marie Ptaszynski, MD, Sagar Lonial, MD
Journal: Blood
Blood (2012) 120 (21): 449.
https://doi.org/10.1182/blood.V120.21.449.449
Published: 2012
Journal Articles

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Sagar Lonial, MD, Adam Cohen, Jeffrey Zonder, MD, William I Benzinger, MD, Jonathan L. Kaufman, MD, Robert Z. Orlowski, MD, PhD, R. Donald Harvey, PharmD, Raymond Alexanian, M.D., Sheeba K Thomas, M.D., Donna Weber, MD, Duncan Walker, PhD, Brandi Hilder, PhD, Ann Ptaszynski, Jatin J Shah, MD
Journal: Blood
Blood (2011) 118 (21): 2935.
https://doi.org/10.1182/blood.V118.21.2935.2935
Published: 2011
Journal Articles

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

Jatin J Shah, MD, Jeffrey Zonder, MD, Adam Cohen, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, M.D., Sheeba K Thomas, M.D., Donna Weber, MD, Jonathan L. Kaufman, MD, R. Donald Harvey, PharmD, Duncan Walker, PhD, Kevin Litwiler, PhD, Sharon Karan, Brandi Hilder, Ann Marie Ptaszynski, MD, Sagar Lonial, MD
Journal: Blood
Blood (2011) 118 (21): 1860.
https://doi.org/10.1182/blood.V118.21.1860.1860
Published: 2011